Srikanth Radhakrishnan Sells 10,483 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Srikanth Radhakrishnan sold 10,483 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total value of $14,990.69. Following the completion of the sale, the insider directly owned 170,736 shares of the company’s stock, valued at $244,152.48. The trade was a 5.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $1.61 on Friday. The business’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $1.78. The company has a market cap of $66.41 million, a P/E ratio of -1.21 and a beta of 0.07. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. Pulmonx Corporation has a one year low of $1.31 and a one year high of $8.12.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%.The firm had revenue of $22.60 million during the quarter, compared to analysts’ expectations of $21.73 million. On average, sell-side analysts forecast that Pulmonx Corporation will post -1.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently modified their holdings of the stock. Corton Capital Inc. bought a new position in shares of Pulmonx during the second quarter worth about $32,000. Cerity Partners LLC acquired a new stake in Pulmonx during the fourth quarter valued at approximately $27,000. Opal Capital LLC bought a new position in Pulmonx during the 4th quarter worth approximately $29,000. Regatta Capital Group LLC acquired a new position in shares of Pulmonx in the 4th quarter worth approximately $30,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Pulmonx in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Q4 beat — Pulmonx reported EPS of -$0.25 (vs. consensus -$0.39) and revenue of $22.6M (vs. ~ $21.7M), with narrower net loss and improved adjusted EBITDA, signaling operational improvement. Earnings Release / Call
• Positive Sentiment: Liquidity boost — Pulmonx closed a five‑year credit facility for up to $60M (initial $40M draw used to refinance debt, $20M undrawn subject to revenue milestones), extending debt maturities to 2031 and reducing near‑term refinancing risk. Credit Facility Release
• Positive Sentiment: Cost discipline and margins — Management executed a restructuring that cut operating expenses ~11% in Q4 and reported a Q4 gross margin of ~78%, supporting a clearer path toward profitability if sales reaccelerate. Earnings Call Highlights
• Neutral Sentiment: Analyst activity is mixed — D. Boral reaffirmed a Buy with a high $14 PT while Canaccord lowered its target to $5 but kept a Buy — divergent targets can attract trading interest but don’t change fundamentals. Analyst Notes
• Negative Sentiment: Guidance disappointment — 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), indicating a growth pause that limits near‑term upside until commercial momentum returns. Guidance / Results
• Negative Sentiment: Insider selling — multiple Form 4 filings show significant sales by the CEO, general counsel and other officers on March 2, which can amplify downside sentiment and supply pressure. SEC Form 4 (CEO) SEC Form 4 (Other)
• Negative Sentiment: Cost of capital and dilution risk — the new term loan carries a high spread (SOFR + 7% with a floor and PIK option) and includes warrants, improving liquidity but increasing interest expense and potential dilution. Loan / Warrants Coverage

Analyst Ratings Changes

A number of brokerages have commented on LUNG. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a report on Thursday. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group lowered their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.38.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.